Jens Christian Jensenius

Evaluation of complement proteins as screening markers for colorectal cancer

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Evaluation of complement proteins as screening markers for colorectal cancer. / Storm, Line; Christensen, Ib J; Jensenius, Jens C; Nielsen, Hans J; Thiel, Steffen; Danish Study Group on Early Detection of Colorectal Cancer.

In: Cancer Immunology, Immunotherapy, Vol. 64, No. 1, 01.2015, p. 41-50.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Storm, L, Christensen, IJ, Jensenius, JC, Nielsen, HJ, Thiel, S & Danish Study Group on Early Detection of Colorectal Cancer 2015, 'Evaluation of complement proteins as screening markers for colorectal cancer', Cancer Immunology, Immunotherapy, vol. 64, no. 1, pp. 41-50. https://doi.org/10.1007/s00262-014-1615-y

APA

Storm, L., Christensen, I. J., Jensenius, J. C., Nielsen, H. J., Thiel, S., & Danish Study Group on Early Detection of Colorectal Cancer (2015). Evaluation of complement proteins as screening markers for colorectal cancer. Cancer Immunology, Immunotherapy, 64(1), 41-50. https://doi.org/10.1007/s00262-014-1615-y

CBE

Storm L, Christensen IJ, Jensenius JC, Nielsen HJ, Thiel S, Danish Study Group on Early Detection of Colorectal Cancer. 2015. Evaluation of complement proteins as screening markers for colorectal cancer. Cancer Immunology, Immunotherapy. 64(1):41-50. https://doi.org/10.1007/s00262-014-1615-y

MLA

Vancouver

Storm L, Christensen IJ, Jensenius JC, Nielsen HJ, Thiel S, Danish Study Group on Early Detection of Colorectal Cancer. Evaluation of complement proteins as screening markers for colorectal cancer. Cancer Immunology, Immunotherapy. 2015 Jan;64(1):41-50. https://doi.org/10.1007/s00262-014-1615-y

Author

Storm, Line ; Christensen, Ib J ; Jensenius, Jens C ; Nielsen, Hans J ; Thiel, Steffen ; Danish Study Group on Early Detection of Colorectal Cancer. / Evaluation of complement proteins as screening markers for colorectal cancer. In: Cancer Immunology, Immunotherapy. 2015 ; Vol. 64, No. 1. pp. 41-50.

Bibtex

@article{3ef77c79aa5d408baf104f4c2c37982b,
title = "Evaluation of complement proteins as screening markers for colorectal cancer",
abstract = "BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Lack of symptoms results in late detection and increased mortality. Inflammation, including complement activation, plays an important role in tumorigenesis.EXPERIMENTAL DESIGN: The concentrations of nine proteins of the lectin pathway of the complement system were determined using time-resolved immunofluorometric assays. The first cohort investigated comprised a matched case-control study of 95 patients with CRC, 48 patients with adenomas and 48 individuals without neoplastic findings. Based on the results, Collectin-liver 1 (CL-L1), M-ficolin and MAp44 were determined as the most promising biomarkers and were subsequently evaluated in a case-control study of 99 CRC patients, 196 patients with adenomas and 696 individuals without neoplastic bowel lesions.RESULTS: Using logistic regression, we found that CL-L1, M-ficolin and MAp44 levels could significantly distinguish between patients with CRC, patients with adenomas and individuals without neoplastic bowel lesions. Higher levels of CL-L1 or MAp44 were associated with lower odds of CRC (OR 0.42 (0.25-0.70) p = 0.0003 and OR 0.39 (0.23-0.65) p = 0.0003, respectively), whereas higher levels of M-ficolin were associated with higher odds of CRC compared to individuals without CRC (OR 1.94 (1.46-2.59) p < 0.0001). The combination of CL-L1, M-ficolin and MAp44 in a test of CRC versus individuals without CRC resulted in 36 % sensitivity at 83 % specificity.CONCLUSION: CL-L1, M-ficolin and MAp44 in combination discriminate between CRC and patients without cancer. The markers did not have sufficient discriminatory value for CRC detection, but may prove useful for screening when combined with other markers.",
keywords = "Adenoma, Aged, Case-Control Studies, Colorectal Neoplasms, Complement System Proteins, Early Detection of Cancer, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Pilot Projects, Prognosis, Tumor Markers, Biological",
author = "Line Storm and Christensen, {Ib J} and Jensenius, {Jens C} and Nielsen, {Hans J} and Steffen Thiel and {Danish Study Group on Early Detection of Colorectal Cancer}",
year = "2015",
month = jan,
doi = "10.1007/s00262-014-1615-y",
language = "English",
volume = "64",
pages = "41--50",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Evaluation of complement proteins as screening markers for colorectal cancer

AU - Storm, Line

AU - Christensen, Ib J

AU - Jensenius, Jens C

AU - Nielsen, Hans J

AU - Thiel, Steffen

AU - Danish Study Group on Early Detection of Colorectal Cancer

PY - 2015/1

Y1 - 2015/1

N2 - BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Lack of symptoms results in late detection and increased mortality. Inflammation, including complement activation, plays an important role in tumorigenesis.EXPERIMENTAL DESIGN: The concentrations of nine proteins of the lectin pathway of the complement system were determined using time-resolved immunofluorometric assays. The first cohort investigated comprised a matched case-control study of 95 patients with CRC, 48 patients with adenomas and 48 individuals without neoplastic findings. Based on the results, Collectin-liver 1 (CL-L1), M-ficolin and MAp44 were determined as the most promising biomarkers and were subsequently evaluated in a case-control study of 99 CRC patients, 196 patients with adenomas and 696 individuals without neoplastic bowel lesions.RESULTS: Using logistic regression, we found that CL-L1, M-ficolin and MAp44 levels could significantly distinguish between patients with CRC, patients with adenomas and individuals without neoplastic bowel lesions. Higher levels of CL-L1 or MAp44 were associated with lower odds of CRC (OR 0.42 (0.25-0.70) p = 0.0003 and OR 0.39 (0.23-0.65) p = 0.0003, respectively), whereas higher levels of M-ficolin were associated with higher odds of CRC compared to individuals without CRC (OR 1.94 (1.46-2.59) p < 0.0001). The combination of CL-L1, M-ficolin and MAp44 in a test of CRC versus individuals without CRC resulted in 36 % sensitivity at 83 % specificity.CONCLUSION: CL-L1, M-ficolin and MAp44 in combination discriminate between CRC and patients without cancer. The markers did not have sufficient discriminatory value for CRC detection, but may prove useful for screening when combined with other markers.

AB - BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Lack of symptoms results in late detection and increased mortality. Inflammation, including complement activation, plays an important role in tumorigenesis.EXPERIMENTAL DESIGN: The concentrations of nine proteins of the lectin pathway of the complement system were determined using time-resolved immunofluorometric assays. The first cohort investigated comprised a matched case-control study of 95 patients with CRC, 48 patients with adenomas and 48 individuals without neoplastic findings. Based on the results, Collectin-liver 1 (CL-L1), M-ficolin and MAp44 were determined as the most promising biomarkers and were subsequently evaluated in a case-control study of 99 CRC patients, 196 patients with adenomas and 696 individuals without neoplastic bowel lesions.RESULTS: Using logistic regression, we found that CL-L1, M-ficolin and MAp44 levels could significantly distinguish between patients with CRC, patients with adenomas and individuals without neoplastic bowel lesions. Higher levels of CL-L1 or MAp44 were associated with lower odds of CRC (OR 0.42 (0.25-0.70) p = 0.0003 and OR 0.39 (0.23-0.65) p = 0.0003, respectively), whereas higher levels of M-ficolin were associated with higher odds of CRC compared to individuals without CRC (OR 1.94 (1.46-2.59) p < 0.0001). The combination of CL-L1, M-ficolin and MAp44 in a test of CRC versus individuals without CRC resulted in 36 % sensitivity at 83 % specificity.CONCLUSION: CL-L1, M-ficolin and MAp44 in combination discriminate between CRC and patients without cancer. The markers did not have sufficient discriminatory value for CRC detection, but may prove useful for screening when combined with other markers.

KW - Adenoma

KW - Aged

KW - Case-Control Studies

KW - Colorectal Neoplasms

KW - Complement System Proteins

KW - Early Detection of Cancer

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Pilot Projects

KW - Prognosis

KW - Tumor Markers, Biological

U2 - 10.1007/s00262-014-1615-y

DO - 10.1007/s00262-014-1615-y

M3 - Journal article

C2 - 25261356

VL - 64

SP - 41

EP - 50

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 1

ER -